| abstract |
Compounds of Formula 1 wherein R is selected from the group consisting of R2, R2NH-, or R3R4N-R5-, and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof. The invention provides a method of inhibiting cell cycle progression, a method of inhibiting cyclin dependent kinases, particularly cdk-2, a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms, a composition comprising an assayable amount of a compound of Formula (I) in admixture or otherwise in association with an inert carrier, and a pharmaceutical composition comprising an effective inhibitory amount of a compound of Formula (I) in admixture of otherwise in association with one or more pharmaceutically acceptable carriers or excipients. |